Evidence map›Paper›PMID 35569347›Full record

ArticleStem cell research2022

CD1d expression demarcates CDX4+ hemogenic mesoderm with definitive hematopoietic potential.

J Philip Creamer, Stephanie A Luff, Hao Yu, Christopher M Sturgeon

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J Philip CreamerDepartment of Medicine, Division of Hematology, Washington University School of Medicine, St. Louis, MO, United States.
Stephanie A LuffDepartment of Medicine, Division of Hematology, Washington University School of Medicine, St. Louis, MO, United States; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY, United States.
Hao YuDepartment of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY, United States.
Christopher M SturgeonDepartment of Medicine, Division of Hematology, Washington University School of Medicine, St. Louis, MO, United States; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai School of Medicine, New York, NY, United States. Electronic address: christopher.sturgeon@mssm.edu.
Washington University in St. Louis · USIcahn School of Medicine at Mount Sinai · US

Funding

PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1M
Embryonic natural killer cell development and functionR01HL151777 · NHLBI · WASHINGTON UNIVERSITY · PI PALIS, JAMES, STURGEON, CHRISTOPHER MICHAEL · 2020 to 2023
$2.3M
Mesodermal Commitment of the Definitive Hematopoietic ProgramR01HL145290 · NHLBI · WASHINGTON UNIVERSITY · PI STURGEON, CHRISTOPHER MICHAEL · 2019 to 2023
$2.1M
NHLBI NIH HHS R01 HL145290NHLBI NIH HHS R01 HL151777NHLBI NIH HHS T32 HL007088
6 · The paper itself

Abstract

To achieve efficient, reproducible differentiation of human pluripotent stem cells (hPSCs) towards specific hematopoietic cell-types, a comprehensive understanding of the necessary cell signaling and developmental trajectories involved is required. Previous studies have identified the mesodermal progenitors of extra-embryonic-like and intra-embryonic-like hemogenic endothelium (HE), via stage-specific WNT and ACTIVIN/NODAL, with GYPA/GYPB (CD235a/b) expression serving as a positive selection marker for mesoderm harboring exclusively extra-embryonic-like hemogenic potential. However, a positive mesodermal cell-surface marker with exclusively intra-embryonic-like hemogenic potential has not been identified. Recently, we reported that early mesodermal expression of CDX4 critically regulates definitive HE specification, suggesting that CDX4 may act in a cell-autonomous manner during hematopoietic development. To identify CDX4+ mesoderm, we performed single cell (sc)RNAseq on hPSC-derived mesodermal cultures, revealing CDX4

Indexed as

HemangioblastsPluripotent Stem CellsAntigens, CD1dAntigens, CD34Cell DifferentiationGlycophorinsHematopoiesisHematopoietic Stem CellsHomeodomain ProteinsHumansMesodermAntigens, CD1dAntigens, CD34CD1D protein, humanCDX4 protein, humanGlycophorinsGYPB protein, humanHomeodomain ProteinsCD1dCDXDefinitive hematopoiesisHemogenic endotheliumHemogenic mesodermHuman pluripotent stem cells

Identifiers

PMID35569347
PMCPMC9193610
OpenAlexW4229332830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.